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Summary
Introduction:  Thirty-ﬁve  to  40  days’  thromboprophylaxis  is  recommended  following  total  hip
replacement  (THR).  Low  molecular  weight  heparin  (LMWH)  injected  by  a  health  professional
ensures good  compliance.  Compliance  with  recent  oral  anticoagulants  has  not  been  precisely
assessed.  Oral  self-administration,  without  coagulation  monitoring  tests,  may  be  a  worrying
issue in  the  management  of  what  is  a  potentially  catastrophic  adverse  event,  without  prodromal
symptoms  alerting  the  patient  to  the  need  for  regular  intake  throughout  the  prescription  period.
Hypothesis:  It  was  hypothesized  that  compliance  with  these  new  oral  anticoagulants  is  good
over the  entire  treatment  period.
Patients  and  method:  The  present  cohort  study  prospectively  assessed  compliance  with  oral
medication  (two  capsules  of  dabigatran  etexilate  [Pradaxa®]  per  day  in  a  single  dose  at  a
set time)  following  THR.  An  electronic  device  continuously  monitored  the  day  and  time  of
extraction of  capsules  from  the  package.  All  included  patients  underwent  clinical  and  echo-
Doppler examination  at  day  30  ±  5  after  the  start  of  the  study.
Results:  Fifty-six  patients  were  included  at  their  discharge  home.  Overall  compliance  was  98.1%
(3,188/3246  capsules  correctly  taken),  falling  off  slightly  over  time  but  never  below  97.1%.  One
patient was  diagnosed  with  symptomatic  thrombophlebitis  34  days  postoperatively,  associated
 11.  End  of  follow-up  echo-Doppler  found  four  cases  of  asymptomaticwith non-compliance  at  day
distal venous  thrombosis.  There  were  no  hemorrhagic  complications.
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Discussion:  The  risk  of  thromboembolic  complications  diminishes  over  time,  while  oral  antico-
agulants  have  a  wide  therapeutic  window  and  relatively  long  half-life  (15—17  hrs).  Efﬁcacy  was
demonstrated,  with  improved  patient  comfort  and  cost-saving.  Compliance  in  the  present  series
was satisfactory.  This,  however,  should  not  mean  that  patients  not  be  appropriately  informed,
as in  the  present  study,  so  as  to  improve  compliance.
Level  of  evidence:  Level  III,  prospective  diagnostic.
© 2012  Published  by  Elsevier  Masson  SAS.
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device  was  analyzed  on  a  dedicated  computerized  reader.
Failure  to  take  one  or  more  capsules  or  a  delay  of  more  than
12  and  less  than  24  hours  was  counted  as  non-compliance.
Taking  more  than  two  capsules  (‘‘over-compliance’’)  was
also  counted  as  non-compliance,  although  the  speciﬁc  risks
entailed  are  different.  Compliance  was  calculated  per  dayIntroduction
Total  hip  replacement  (THR)  is  classiﬁed  as  at  high  throm-
bosis  risk  (deep  venous  thrombosis  [DVT]  and  pulmonary
embolism  [PE]).  American  [1]  and  French  [2,3]  consensus
conferences  recommended  prolonged  35—42  days  throm-
boprophylaxis  following  THR.  In  France,  this  has  been
implemented  by  injection  of  low  molecular  weight  heparin
(LMWH),  with  twice-weekly  platelet  monitoring  due  to  the
risk  of  heparin-induced  thrombopenia  (HIT).  The  only  oral
anticoagulant  available  was  anti-vitamin  K  (AVK);  compli-
ance  could  be  checked  on  the  International  Normalized  Ratio
(INR).  However,  difﬁculty  of  use,  narrow  implementation
window  [4]  and  risk  of  hemorrhage  [5],  mainly  due  to  misuse,
led  to  AVK  being  abandoned  in  most  cases  as  a  preven-
tive  treatment  for  postoperative  thrombosis  in  orthopedic
surgery.
Recently,  new  oral  anticoagulants  have  come  onto  the
market:  dabigatran  etexilate  (Pradaxa®),  an  anti-IIa,  and
rivaroxaban  (Xarelto®),  an  anti-Xa,  with  ofﬁcial  approval
for  prescription  following  THR  and  total  knee  replacement
(TKR).  Apixaban  (Eliquis®),  an  anti-Xa,  is  to  come  onto
the  market  soon.  They  are  administered  orally  and  do  not
require  blood  tests.  In  addition  to  comfort  for  the  patient,
who  no  longer  undergoes  daily  injection  and  weekly  blood
sampling,  cost-saving  is  also  signiﬁcant  [6].
These  oral  anticoagulants  raise  the  issue  of  compliance
[7]  for  the  medical  community,  as  their  administration  is
entirely  the  responsibility  of  the  patient  after  discharge
home.  The  present  study  therefore  sought  to  assess  compli-
ance  to  oral  thromboprophylaxis  following  THR  and  the
possible  consequences  of  non-compliance.  The  hypothesis
was  that  compliance  is  good  throughout  the  treatment  pre-
scribed  for  non-dependent  patients  discharged  home.
Patients and method
Patients
A  prospective  continuous  cohort  study,  with  university
funding  and  ethics  committee  approval,  included  patients
undergoing  ﬁrst-line  THR  in  the  Caen  University  Hospital
Center  (France)  between  November  2,  2009  and  July  28,
2010  and  receiving  oral  dabigatran  etexilate,  at  a single
dose  of  two  110  mg  capsules  per  day.  Other  inclusion  criteria
were:  age  18—75  years,  and  consent  following  written  and
oral  information  (although  no  speciﬁc  booklet  or  treatment
education  was  provided).  Exclusion  criteria  were:  discharge
to  another  institution,  previous  long-course  anticoagulant Freatment,  low  dabigatran  etexilate  dose  indicated  accord-
ng  to  the  marketing  authorization  (moderate  or  severe  renal
nsufﬁciency  (creatinine  clearance  less  than  50  mL/min),
iver  enzyme  (alanine  aminotransferase)  level  more  than  2-
old  normal  threshold,  weight  less  than  50  kg,  patient  under
miodarone  or  quinidine),  or  adult  patient  under  guardian-
hip.
ethods
hromboprophylaxis  was  initiated  toward  the  end  of  the
ay  of  the  THR.  The  study  as  such  began  at  discharge,
or  30  ±  5  days  (herein,  S1  (ﬁrst  day  of  study,  at  discharge)
o  S30  ±  5).  At  home,  each  patient  had  60  capsules  of
abigatran  etexilate  110  mg:  i.e.,  30  days’  treatment.  An
lectronic  device  was  glued  to  each  blister  of  the  pack
Fig.  1)  and  recorded  the  date  and  time  each  capsule  was
aken  (ABR  PharmaTM).  Packaging  was  not  otherwise  modi-
ed.
ssessment
ognitive  status  on  the  Mini-Mental  State  (MMS)  [8],  his-
ory  and  socio-economic  activity  were  recorded  at  inclusion.
 clinical  and  echo-Doppler  check-up  for  thromboembolic
vents  was  performed  at  S30  ±  5  to  analyze  the  conse-
uences  of  any  non-compliance;  any  proximal  and  distal
hromboses  were  noted.  At  this  check-up,  the  electronicigure  1  Blister  pack  with  electronic  monitoring  device.
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Table  1  Non-inclusion  criteria.
Reason  for  exclusion  Number  of  patients
Discharge  to  institution  48
Age >  75  years  29
Age <  18  years  1
AVK treatment  10
ALAT >  2-fold  normal  2
Creatinine  clearance  <  50  mL/min 6
Weight  <  50  kg 1
Refusal 9
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Table  2  Day  of  non-compliance  after  day  of  discharge  (S).
Patient  Reason  for
non-compliance
Day  S  n  capsules
concerned
1 Forgot  S20  2
Forgot  S26  2
Forgot  S30  2
5 Forgot  S8  2
14 Over-compliance  (3) S1  1
Over-compliance  (3) S2 1
20 Forgot S18 2
21 Forgot S13 2
22 Forgot  S8  2
24 Forgot  S12  2
Forgot S19  2
28 Forgot S27 2
30 Forgot S9 2
31 Forgot S28 2
34 Forgot S10 2
35 Forgot S13 2
Forgot S17 2
Forgot S18 2
39 Forgot S14 2
Forgot  S27  2
47 Forgot  S3  2
51 Forgot  S30  2
54 12—24  hours  late  S29  2
55 Forgot  S3  2
Forgot  S17  2
Forgot  S18  2
Forgot  S19  2
56 Forgot  S14  2
Forgot  S26  2
57 Forgot  S15  2
Total  58
r
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egory  or  long-course  treatment.
During  the  study  period,  one  patient  showed  symp-
tomatic  thrombosis  at  S28,  2  days  before  termination  of
Table  3  Number  of  patients  according  to  reason  for  non-
compliance.
Reason  for  non-compliance  Number  of  patients
4  omissions  1
3 omissions  2
2 omissions  3
1 omission  11Total 106
s  the  ratio  between  cases  of  non-compliance  in  terms  of
ose  or  time  and  the  theoretic  number  of  doses.
tatistics
atients  were  assigned  to  one  or  two  categories  according
o  results:  compliant  or  imperfectly  compliant.  Qualitative
ariables  were  compared  by  Fisher’s  exact  test,  and  quanti-
ative  variables  were  compared  between  groups  by  Anova.
he  signiﬁcance  threshold  was  set  at  0.05.
esults
ne  hundred  and  sixty-eight  THRs  were  performed  during
he  9  months  of  the  study  period;  62  patients  were  included.
able  1  shows  the  reasons  for  exclusion  of  the  other  106.
wo  of  the  62  patients  were  excluded  while  in  hospital,
efore  the  start  of  the  study  (one  venous  thrombosis  with
urative  treatment  before  discharge;  one  postoperative  THR
islocation  with  surgical  revision).  Four  of  the  60  patients
ho  handed  in  their  electronic  device  were  excluded:  two
or  device  defects,  one  for  defective  device  use,  and  one
ho  had  ceased  treatment  due  to  headache  (LMWH  therapy
ursued  by  the  patient’s  family  doctor).  Electronic  device
nalysis  thus  concerned  56  patients  (Fig.  2)  for  a  theoretic
246  capsules  between  S1  and  the  day  of  the  clinical/echo-
oppler  check-up  (S30  ±  5).
Over  the  treatment  period,  3188  capsules  were  taken
n  good  compliance  with  the  prescribed  time  of  adminis-
ration.  Overall  compliance  was  98.21%.  Nineteen  patients
howed  one  or  more  cases  of  non-compliance,  including
 withy  ‘‘over-compliance’’  (three  instead  of  two  cap-
ules  on  study  days  1  and  2)  without  resultant  hemorrhage
Tables  2  and  3).  Compliance  fell  regularly  over  successive
-day  periods  (Fig.  3)  but  not  below  97%  between  S26  and
30.  During  the  ﬁrst  10  days  (S1—S10),  seven  patients  showed
ncomplete  compliance;  six  forgot  a  dose  and  one  ‘‘over-
omplied’’.  Overall  compliance  for  this  period  was  98.5%
or  98.9%  taking  account  only  of  the  risk  of  insufﬁcient  pro-
hylaxis)  (Fig.  4).
Table  4  presents  patient  data  at  inclusion  and  per  group
compliant  vs.  incompletely  compliant).  Statistical  analy-
is  found  compliant  patients  to  be  signiﬁcantly  more  often
etired  or  in  early  retirement  (P  =  0.009);  retired  patients
ere  signiﬁcantly  older  (mean,  65.51  ±  4.92  years)  than
he  others  (mean,  51.18  ±  8.64  years;  P  <  00.0001).  Patientseceiving  THR  for  osteonecrosis  were  signiﬁcantly  younger
P  <  0.001)  than  those  operated  on  for  osteoarthritis  (48.3  vs.
1.5  years),  and  more  frequently  in  the  incomplete  compli-
nce  group  (P  =  0.037).  On  the  other  hand,  no  signiﬁcant
nter-group  differences  emerged  for  gender,  age  MMS  cat-12—24 hours  late  1
Over-compliance  1
Total 19
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Figure  2  Flow  chart  of  patients  
thromboprophylaxis  (or  D34  post-surgery);  he  was  in  the
incomplete  compliance  group,  with  non-compliance  at  S3
(D10  post-THR).  Echo-Doppler  found  proximal  thrombosis,
managed  by  curative  anticoagulants.
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Figure  3  Percentage  compliance  by  period  of  5  days.
94 
95 
96 
97 
98 
99 
100 
S1  S2  S3  S4  S5  S6 S7 S8 S9 S10 
Study day (aer discharge)
% 
Figure  4  Percentage  compliance  during  the  ﬁrst  10  days.
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tleaving  study  after  inclusion.
Fifty-ﬁve  patients  underwent  clinical  check-up  at
30  ±  5,  one  patient  having  had  a  negative  echo-Doppler.
ive  had  clinical  check-up  without  echo-Doppler;  none
howed  clinical  signs  of  venous  thromboembolism  (Table  5).
n  the  55  echo-Dopplers,  four  asymptomatic  distal  throm-
oses  were  found  at  S30  ±  5:
 two  suggesting  thrombosis  in  regression  or  thrombosis
sequelae,  leading  to  cessation  of  preventive  anticoagu-
lants;
 two  distal  thromboses,  in  which  anticoagulant  therapy
was  continued;  one  of  these  patients  had  a  history  of
post-surgical  venous  thrombosis.
These  four  patients  were  in  the  complete  compliance
roup.
There  were  no  revisions  for  hemorrhagic  complications,
ncluding  the  ‘‘over-compliant’’  patient  who  took  three  cap-
ules  at  S1  and  S2.
iscussion
he  present  study  sought  to  measure  precisely  the  degree
f  compliance  with  oral  thromboprophylaxis  following  THR,
nd  to  assess  the  possible  consequences  of  non-compliance.
he  study  hypothesis  was  conﬁrmed,  with  an  overall  compli-
nce  rate  of  98.1%.  This  is  a  short  preventive  treatment,  in
hich  the  patient  is  not  stimulated  to  comply  by  symptoms.
he  impact  of  therapeutic  education  in  long-course  treat-
ent  remains  to  be  demonstrated  [4].  As  in  the  case  of  any
rug,  the  patient  should  receive  the  most  complete  infor-
ation  possible  at  the  time  of  prescription  [9];  this  was  the
ase  in  the  present  study,  where  all  patients  were  informed
f  the  study  design  and  objectives.  No  speciﬁc  documentary
nformation,  however,  was  given  to  the  patient  except  for
he  information  letter  approved  by  the  ethics  committee.
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Table  4  Patient  data  collected  before  discharge.
Overall
population
n  =  56
Compliant  n  =  37  Incompletely
compliant  n  =  19
P
Clinical
Age  (years),  mean  (SD)  60  (9.75)  60.68  (8.16)  56  (11.9)  0.089
Male, n  (%)  34  (60.7)  20  (54.05)  14  (73.68)  0.25
Body-mass index,  mean  (SD) 27.48  (5.45)  27.66  (6.07)  27.13  (4.1)  0.73
Charnley score
A  =  n  (%) 37  (66) 23  (62.16) 13  (68.42) 0.77
B =  n  (%) 18  (32) 13  (35.13) 6  (31.58) 0.36
C =  n  (%) 1  (2) 1  (2.7) 0  (0) 1
Occupational  status
Working  =  n  (%)  16  (28.6)  11  (29.73)  5  (26.32)  1
Retired or  in  early  retirement  =  n  (%)  32  (57.14)  26  (70.27)  6  (31.58)  0.009
Sick leave  =  n  (%)  4  (7.14)  0  (0)  4  (21.05)  0.01
Invalidity =  n  (%)  1  (1.78)  0  (0)  1  (5.26)  0.34
Unemployed  =  n  (%)  1  (1.78)  0  (0)  1  (5.26)  0.34
Missing data  =  n  (%)  2  (3.56)  0  (0)  2  (10.53)
Housing
House =  n  (%)  49  (87.5)  33  (89.2)  16  (84.21)  0.67
Apartment =  n  (%)  5  (8.93)  4  (10.8)  1  (5.2)  0.65
Missing data  =  n  (%)  2  (3.57)  0  (0)  2  (10.5)
Number of  persons  at  home
> 2  =  n  (%)  12  (21.43)  8  (21.62)  4  (21.05)  1
≤ 2  =  n  (%)  41  (73.2)  29  (78.38)  12  (63.16)  0.34
Missing data  =  n  (%) 3  (5.36)  0  (0)  3  (15.79)
Comorbidity
Long-course  treatment  =  n  (%)  23  (41)  14  (37.84)  9  (47.37)  1
MMS
Score A:  mean  orientation/10 9.86 9.84 9.89  0.62
Score B:  mean  learning/3 3.00 3.00 3.00 1
Score  C:  mean  attention/calculation/5 4.54 4.57 4.47  0.76
Score D:  mean  recall  memory/3 2.68 2.73 2.58 0.36
Score  E:  mean  language/8 7.88 7.84 7.95 0.24
Score  F:  mean  motor  activity/1  0.95  0.97  0.89  0.21
Total score:  mean  MMS/30  28.89  28.95  28.79  1
THR indication
Osteoarthritis,  =  n  (%)  47  (84)  35  (94.59)  12  (63.16)  0.005
Osteonecrosis  =  n  (%)  7  (12.5)  2  (5.41)  5  (26.32)  0.037
Hospital stay
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hMean  days  (SD)  6.25  (1.05)  
his  letter  may  have  inﬂuenced  compliance,  in  a  positive
irection,  but  was  integral  to  good  clinical  practice.
This  was  the  ﬁrst  study  of  compliance  in  primary
hort-course  thromboprophylaxis.  Previous  reports  focused
n  long-course  regimes,  secondary  prevention  or  curative
reatment  for  known  pathologies,  with  compliance  rang-
ng  from  31%  to  83%  [7,10]. Compliance  was  found  to
iminish  over  time  [11,12],  whatever  the  pathology  [7];  in
ong-course  treatment,  non-compliance  impacted  efﬁcacy
13,14]  and  mortality  [15]. The  present  study  likewise  found
 fall  in  compliance  over  time,  although  remaining  greater
han  97%.
e
c
a
t6.35  (1.03)  5.68  (1.73)  0.07
Dabigatran  etexilate  was  chosen  as  being  the  ﬁrst  of
he  new  oral  anticoagulants  to  receive  market  authoriza-
ion  for  this  indication  in  France.  The  daily  2-capsule
ose  might  tend  to  increase  the  risk  of  poor  compliance
7,16].  The  original  electronic  device  recorded  administra-
ion  time  without  undoing  the  packaging;  the  electronic
ill-dispenser  used  in  most  compliance  studies  would  not
ave  been  suitable  for  a  2-capsule  dose,  and  moreover
ntails  repackaging.  Blood  assay  could  have  been  used  to
heck  compliance,  but  might  have  biased  it  and,  above
ll,  would  have  made  this  observational  study  interven-
ional.
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Table  5  Data  at  S30  ±  5.
Total  population  n  =  56  Compliant  n  =  37  Incompletely
compliant  n  =  19
P
Clinical  events
Symptomatic  thrombotic  event  =  n  (%)  1  (1.78)  0  (0)  1  (5.26)  0.34
Hemorrhage =  n  (%)  0  (0)  0  (0)  0  (0)  1
Echo-Doppler
Mean time  to  echo-Doppler  (days)  (n  [SD])  34  (7.8)  33  (5.6)  36  (11)
Number of  patients  51  35  16
Thrombosis (n  [%]) 5  (9.8) 4  (11.43) 1  (6.25) 1
Proximal  thrombosis  (n  (%)) 1  (1.  96) 0  (0) 1  (6.25)
Distal thrombosis  n  (%) 4  (7.84) 4  (11.43) 0  (0)
Administration
Patient took  out  own  capsules  (n  [%])  50  (89.3)  34  (91.89)  16  (84.21)  0.39
Capsules taken  out  for  patient  (n  [%])  5  (8.9)  2  (5.4)  3  (15.79)
Missing data  (n  [%])  1  (1.78)  1  (2.7)  0  (0)
Walking perimeter
>  500  m  (n  [%]) 32  (57.14) 21  (56.76) 11  (57.89) 1
100—500 m  (n  [%])  11  (19.64) 9  (24.32) 2  (10.53)
50—100 m  (n  [%])  5  (8.93) 4  (10.81) 1  (5.26)
Only at  home  (n  [%]) 4  (7.14) 2  (5.41) 2  (10.53)
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eMissing data  (n  [%]) 4  (7.14)
Patients  on  a  low-dose  regime  were  excluded  in  order
to  avoid  methodological  error.  The  non-inclusion  rate  in
the  study  was  high.  All  those  discharged  to  an  institu-
tion  where  care-staff  administer  medication  were  excluded.
This  was  also  the  reason  for  restricting  the  study  to  THR:
in  our  institution,  TKR  cases  are  systematically  discharged
to  a  rehabilitation  center.  The  population  may  thus  seem
to  have  been  selected,  but  in  practice  matched  a  pop-
ulation  undergoing  postoperative  care  at  home:  younger,
with  less  dependence  or  comorbidity  than  the  general
THR  population.  This  is  the  population  bearing  responsibil-
ity  for  their  own  treatment.  In  the  present  study,  family
members  administered  the  capsules  in  ﬁve  cases:  two
were  compliant,  and  three  committed  at  least  one  omis-
sion.
The  risk  of  symptomatic  venous  thrombosis  following
THR  ranges  in  the  literature  from  1.3%  to  2.7%  [3,5,17,18],
with  a  13%  rate  of  asymptomatic  venous  thrombosis  [3,17].
A  35—40  days  preventive  anticoagulant  regime  has  been
shown  to  reduce  thrombosis  risk  from  3.3%  to  1.3%  [18].
The  risk  of  major  hemorrhagic  accident  is  0.7%  to  0.9%
[3,19],  and  higher  in  the  ﬁrst  10  postoperative  days  [20],
at  0.1—3.1%  [21]. The  present  study  was  not  intended  to
demonstrate  drug  efﬁcacy;  the  observed  events  rate,  how-
ever,  was  comparable  to  that  in  the  literature.  The  risk  of
thrombosis  diminishes  over  time  (with  distance  from  surgery
and  resumption  of  walking);  it  is  particularly  high  during  the
ﬁrst  15—17  days  post-surgery  [5,22]. The  two  distal  throm-
boses  found  on  echo-Doppler  at  end  of  follow-up  received
no  curative  treatment,  as  continuation  of  the  preventive
doses  was  sufﬁcient  [23]. During  the  ﬁrst  15—17  days,  seven
patients  showed  non-compliance.  Only  one,  with  omission
at  postoperative  day  10,  showed  symptomatic  DVT;  no
causal  relation  can,  obviously,  be  proven.  Patient  14  took  a
D
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igher  dose  of  anticoagulants  than  prescribed,  but  without
emorrhage.  Other  omissions  had  no  detectable  clinical
mpact.  The  12  patients  with  later  non-compliance  suf-
ered  no  thromboembolic  consequences.  With  a  half-life
f  17  hours,  the  equilibrium  state  of  dabigatran  etexilate
s  extinguished  after  3  days’  treatment  [9,24]. The  conse-
uences  of  omission  are  less  than  with  molecules  of  longer
alf-life  [4].  There  is  no  thrombotic  rebound  effect  with
nd  of  treatment  [25]. The  efﬁcacy  of  oral  anticoagulants
s  now  proven  [19,23,25,26]; over  and  above  the  comfort
f  the  patient,  who  is  not  subjected  to  daily  injection  and
eekly  blood  sampling,  they  also  entail  substantial  cost-
aving  [6].
Comparing  the  complete  and  incomplete  compliance
roups  found  no  age  difference,  although  non-retired
atients  and  those  operated  on  for  osteonecrosis  were
igniﬁcantly  younger  and  less  compliant.  To  maximize
ompliance,  especially  in  younger  patients,  the  prescriber
eeds  to  inform  the  patient  and  explain  the  prescription,
articularly  in  preventive  treatment  [9,12].
The  question  arises  of  compliance  with  long-course  oral
reatment,  notably  in  cardiological  indications  [13]. Recent
tudies  of  respectively  18,113  [27]  and  14,264  patients  [28]
t  2  years’  follow-up  at  least  demonstrated  non-inferiority
ith  respect  to  warfarin.  It  follows  that  either  compliance
as  satisfactory  or  incomplete  compliance  was  compatible
ith  good  results  in  comparison  to  a  treatment  in  which
fﬁcacy  is  controlled.isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
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